A Form 4 filed on September 4, 2026, discloses that David Baxley Spetzler, President of Caris Life Sciences, Inc. (NASDAQ:CAI), exercised stock options and sold common shares on September 3 and September 4, 2026, in a broker-assisted sell-to-cover transaction tied to options scheduled to expire on September 12, 2026.

Key Highlights

  • Option exercises: Spetzler exercised 1,000,000 stock options on September 3, 2026, and 250,000 stock options on September 4, 2026, each at an exercise price of $2.44 per share.
  • Shares sold on September 3: 393,100 shares at a weighted average price of $24.7604 and 84,900 shares at a weighted average price of $25.3201.
  • Shares sold on September 4: 119,212 shares at a weighted average price of $24.7552.
  • Purpose of sales: According to the filing, shares were sold "solely to cover the aggregate exercise price and applicable tax withholding obligations," with Spetzler retaining all remaining shares acquired upon exercise.
  • Remaining beneficial ownership: Following all reported transactions, Spetzler directly beneficially owned 1,182,871 shares of common stock.
  • Options fully vested: The filing states the stock options exercised were fully vested and scheduled to expire on September 12, 2026.

Spetzler's Sell-to-Cover Option Exercise at Caris Life Sciences

According to the filing, David Baxley Spetzler, President of Caris Life Sciences, Inc., conducted a broker-assisted sell-to-cover exercise of fully vested stock options across two days. On September 3, 2026, he exercised 1,000,000 options at $2.44 per share, acquiring 1,000,000 shares of common stock. He then sold 393,100 shares at a weighted average price of $24.7604, with individual transaction prices ranging from $24.3200 to $25.3100, and an additional 84,900 shares at a weighted average price of $25.3201, with prices ranging from $25.3200 to $25.3300.

On September 4, 2026, Spetzler exercised an additional 250,000 options at $2.44 per share and sold 119,212 shares at a weighted average price of $24.7552, with transaction prices ranging from $24.5550 to $25.1200. The filing notes all three sale tranches involved weighted average prices, and Spetzler has undertaken to provide full per-transaction price details to Caris Life Sciences, any security holder, or SEC staff upon request.

The filing states the sales were effected pursuant to a broker-assisted sell-to-cover arrangement tied to options set to expire on September 12, 2026, and that Spetzler "retained all remaining shares acquired upon exercise." After all transactions, his direct beneficial ownership stood at 1,182,871 shares. The second stock option tranche of 250,000 options reached zero remaining derivative securities following the September 4 exercise, while no derivative securities were reported as remaining after both tranches were fully exercised.

What Was Disclosed

The filing reports that Caris Life Sciences President David Baxley Spetzler exercised 1,250,000 stock options at $2.44 each and sold 597,212 shares over September 3-4, 2026, solely to cover exercise costs and tax obligations, retaining the balance and holding 1,182,871 shares directly afterward.